OVID
NASDAQ
US
Ovid Therapeutics Inc. - Common Stock
$2.20
▲ +$0.04
(+1.85%)
Vol 1.4M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$116.1M
ROE
-63.7%
Margin
-549.6%
D/E
0.00
Beta
0.29
52W
$0–$2
Wall Street Consensus
17 analysts · Apr 20267
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
94.1%
Buy Rating
Price Chart
Similar Stocks
GLSI
Greenwich Lifesciences Inc
$291.1M
PALI
Palisade Bio Inc
$350.2M
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
FHTX
Foghorn Therapeutics Inc
$305.4M
ORGO
Organogenesis Holdings Inc
P/E 654.1
$657.4M
NBP
NovaBridge Biosciences
$458.9M
AVXL
Anavex Life Sciences Corp
$318.1M
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $-0.13
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.13 | — | — |
| Dec 2025 | $-0.12 | $0.06 | +$0.18 |
| Sep 2025 | $-0.15 | $-0.17 | $-0.02 |
| Jun 2025 | $-0.16 | $-0.06 | +$0.10 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -58.8% | -34.1% | -58.8% | -58.8% | -63.7% | -63.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -74.7% | -4557.1% | -574.0% | -574.0% | -549.6% | -549.6% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.72 | 4.93 | 4.72 | 4.72 | 4.24 | 4.24 |
Key Ratios
ROA (TTM)
-46.1%
P/S (TTM)
17.56
P/B
1.0
EPS (TTM)
$-0.51
CF/Share
$-0.68
Rev Growth 3Y
-86.1%
52W High
$2.01
52W Low
$0.24
$0.24
52-Week Range
$2.01
How does OVID compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
OVID valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
17.6
▲
37%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.0
▼
60%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
OVID profitability vs Biotechnology peers
ROE
-63.7%
▲
5%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-549.6%
▼
92%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-46.1%
▲
1%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
OVID financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.2
▼
4%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.3
▼
70%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
OVID fundamentals radar
OVID
Peer median
Industry
OVID profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio